MLYS

Company Overview — What Does Mineralys Therapeutics, Inc. Do?

We are a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are initially developing for the treatment of patients with uncontrolled hypertension (uHTN), defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension (rHTN), defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic. In the United States, there are over 115 million patients who have sustained elevated blood pressure (BP), or hypertension and more than half of this population fails to achieve their BP goals, defined as BP of 130/80 mmHg, with currently available medications. There are over 30 million treated patients who do not achieve their BP goal, of whom approximately 20 million have systolic BP levels greater than 140 mmHg. Patients with hypertension that persists despite taking two or more medications have 1.8 and 2.5 times greater mortality risk due to either cardiovascular disease or stroke, respectively. In a Phase 2 clinical trial evaluating 200 subjects with uHTN and rHTN (Target-HTN), lorundrostat demonstrated a clinically meaningful and statistically significant reduction in BP with once-daily dosing and was well tolerated. In addition to hypertension, we intend to develop lorundrostat for the treatment of chronic kidney disease (CKD) and believe that our product candidate holds promise to be an innovative solution for the rapidly growing unmet need in multiple cardiorenal disorders. Hypertension is one of the most common medical conditions globally, afflicting approximately 1.3 billion people and resulting in an estimated average of $130 billion annual economic burden in the United States alone between 2003 and 2014. Despite the availability of multiple treatment options, including thiazide diuretics, angiotensin-converting enzyme (ACE)-inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers, beta blockers, and mineralocorticoid receptor antagonists (MRAs), the prevalence of uHTN continues to grow, further exacerbated by the rapidly rising rate of obesity. Over 30 million hypertensive patients in the United States are unable to achieve their BP goal despite treatment. Within this population there are approximately 10.3 million patients suffering from rHTN. Multiple large-scale studies have demonstrated that patients who fail to achieve their BP goal have a significantly elevated risk of developing heart disease, stroke and kidney disease (Wright JT Jr, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116; and Zhou, et al., Uncontrolled Hypertension Increases Risk of All-Cause and Cardiovascular Disease Mortality in US Adults: the NHANES III Linked Mortality Study. Scientific Reports, 2018;8(1):1-7). Patients with rHTN have a 1.5 and 2.3 times higher risk than normotensive patients for composite cardiovascular events and end-stage renal disease, respectively. Notwithstanding this significant and growing unmet need, there has been a lack of U.S. Food and Drug Administration (FDA)-approved novel therapies targeting hypertension, with no new class of antihypertensive treatment approved within the last fifteen years. Abnormally elevated aldosterone levels are a key factor in driving hypertension in approximately 25% of hypertensive patients. Developing an effective hypertension therapy that targets aldosterone synthase remains a significant challenge, given the tight homology between the enzymes that regulate aldosterone and cortisol synthesis, as well as aldosterone’s role in regulating potassium. Several large pharmaceutical companies have tried to develop ASIs, but their efforts have been hampered due to insufficient selectivity for aldosterone, resulting in off-target toxicities associated with cortisol inhibition. These challenges have led to the discontinuation of many ASIs in development to date. We were originally founded as a Delaware corporation on May 31, 2019 under the name Catalys SC1, Inc. On May 29, 2020, we changed our name to Mineralys Therapeutics, Inc. Our principal executive offices are located at 150 N. Radnor Chester Road, Suite F200, Radnor, PA. Mineralys Therapeutics, Inc. (MLYS) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jon Congleton. With a market capitalization of $2.2B, MLYS is one of the notable companies in the Healthcare sector.

Mineralys Therapeutics, Inc. (MLYS) Stock Rating — Reduce (April 2026)

As of April 2026, Mineralys Therapeutics, Inc. receives a Reduce rating with a composite score of 34.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MLYS ranks #3,035 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Mineralys Therapeutics, Inc. ranks #441 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MLYS Stock Price and 52-Week Range

Mineralys Therapeutics, Inc. (MLYS) currently trades at $26.63. The stock lost $0.54 (2.0%) in the most recent trading session. The 52-week high for MLYS is $47.65, which means the stock is currently trading -44.1% from its annual peak. The 52-week low is $10.44, putting the stock 155.1% above its annual trough. Recent trading volume was 982K shares, suggesting relatively thin trading activity.

Is MLYS Overvalued or Undervalued? — Valuation Analysis

Mineralys Therapeutics, Inc. (MLYS) carries a value factor score of 25/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.61x, versus the sector average of 2.75x.

At current multiples, Mineralys Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Mineralys Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Mineralys Therapeutics, Inc. (MLYS) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -27.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -27.0% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MLYS Debt, Balance Sheet, and Financial Health

Mineralys Therapeutics, Inc. has a debt-to-equity ratio of 2.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 43.76x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $218M.

MLYS has a beta of 0.92, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Mineralys Therapeutics, Inc. is 29/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Mineralys Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Mineralys Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.29. Net income for the quarter was $-179M. Operating income came in at $-192M.

In FY 2025, Mineralys Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.29. Net income for the quarter was $-155M. Operating income came in at $-171M.

In Q3 2025, Mineralys Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.52. Net income for the quarter was $-37M. Operating income came in at $-41M.

In Q2 2025, Mineralys Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.66. Net income for the quarter was $-43M. Operating income came in at $-47M.

Over the past 8 quarters, Mineralys Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing MLYS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MLYS Dividend Yield and Income Analysis

Mineralys Therapeutics, Inc. (MLYS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MLYS Momentum and Technical Analysis Profile

Mineralys Therapeutics, Inc. (MLYS) has a momentum factor score of 47/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 62/100 reflects moderate short selling activity.

MLYS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Mineralys Therapeutics, Inc. (MLYS) ranks #441 out of 838 stocks based on the Blank Capital composite score. This places MLYS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MLYS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MLYS vs S&P 500 (SPY) comparison to assess how Mineralys Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

MLYS Next Earnings Date

No upcoming earnings date has been announced for Mineralys Therapeutics, Inc. (MLYS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MLYS? — Investment Thesis Summary

The quantitative profile for Mineralys Therapeutics, Inc. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 25/100 indicates premium valuation. High volatility (stability score 29/100) increases portfolio risk.

In summary, Mineralys Therapeutics, Inc. (MLYS) earns a Reduce rating with a composite score of 34.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MLYS stock.

Related Resources for MLYS Investors

Explore more research and tools: MLYS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MLYS head-to-head with peers: MLYS vs AZN, MLYS vs SLGL, MLYS vs VMD.